Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (2636)	10/13/1998 10:17:00 AM
From: Bob L	Read Replies (1) \| Respond to of 3702

Maurice, your points are interesting. But I will be traveling and away from my computer for 10 days, so I will reply later.

To: Maurice Winn who wrote (2636)	10/24/1998 7:27:00 PM
From: Bob L	Read Replies (2) \| Respond to of 3702

Maurice, returning to your comments on monoclonal "cocktails", here are a couple of thoughts. I'm reluctant to say much here, as I am way beyond my expertise. But I think you are missing a couple of points to consider. First, the issue of bulky disease. As I understand it, these treatments do not reach the inside cells of a large tumor mass, at least not as well as they reach the exterior. So if the patient has a large tumor, sequential treatment may be more effective, to peel off layers of cancer cells as it were. Second, you may not be giving enough consideration to the wide variety of cell structures and types within the general group of "nonhodgkins lymphomas". Suppose treatment A is very effective against cells with follicular small-celled characteristics, and much less effective against diffuse large-celled. Meanwhile treatment B is quite effective against diffuse large-celled. It wouldn't make sense to use treatment A on someone with a clear diagnosis of diffuse large-celled. So you need cocktail candidates that are similar in effectiveness right down to the cellular classification. In other words, there is a lot more to consider than whether the patient is, as you say, "strongly CD-20 positive." Perhaps the researchers will need to find out more about how the treatments work individually before going to combinations. As I said, I'm in way over my head. We need more golfdads with the time to spare to straighten us out on this.